Semaglutide tablet form: what it is and whether it suits you

The misconception most people arrive with

A lot of people assume the tablet is a weaker or 'lite' version of the injection, a stepping stone rather than a treatment in its own right. That is not the case. If you want to understand what the Wegovy tablet form actually involves, it has its own licensed dose range (1.5 mg through to 25 mg), its own trial evidence, and its own MHRA authorisation for weight management in adults. They are a distinct medicine format, not a diluted one.

The clinical trial behind the approval (OASIS 4, running 64 weeks in adults with obesity or overweight alongside at least one weight-related condition) reported an average weight loss of around 13.6% among all participants compared with around 2.4% on placebo. Among those who stayed fully adherent to the treatment schedule throughout, the figure was closer to 17%. That distinction matters: the 17% figure reflects a best-case group, not the average. Both numbers are meaningful; only the first one is the headline. The NHS patient-level information for this oral semaglutide treatment will carry the full trial context once established on the NHS medicines A–Z.

The MHRA's approval announcement from June 2026 is the authoritative UK source on licensing status, and the prescribing information sets out the exact conditions under which the medicine is indicated. A prescriber (not the trial headlines) decides whether it fits your situation.

How the tablet's daily routine affects the decision

This is where many people make up their minds. The injection is once a week. The tablet is once a day, and that daily ritual has real requirements attached: empty stomach, a small amount of plain water only (roughly up to 120 ml), then a 30-minute wait before coffee, breakfast, other medicines, anything. For some people that is completely workable; they take it before the kettle boils and it becomes part of the morning. For others, a chaotic start to the day makes consistent adherence genuinely difficult.

Storage is simpler than the injection. No fridge needed. The tablet can travel in hand luggage without the logistics of keeping a pen cool, which matters if you spend time away from home regularly. If the practicalities of how Wegovy tablets are used day-to-day are a deciding factor for you, that is a reasonable thing to raise with a prescriber, it directly affects whether the treatment works as intended.

The injection, by contrast, suits people who find a weekly routine easier to maintain than a daily one, or who have medical reasons that make absorption via the gut less predictable. Neither format is universally better; the right choice depends on the individual.

Who the tablet is licensed for, and what that means practically

The UK licence covers adults with a BMI of 30 or above, or adults with a BMI between 27 and 29.9 who have at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or prediabetes. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance. BMI alone does not determine approval, a prescriber considers the full clinical picture, including other medicines you take and any relevant history.

One specific consideration: because the tablet is absorbed through the gut and relies on consistent stomach conditions, other oral medicines taken too close to it may affect how well each is absorbed. This includes oral contraceptives. If you take oral contraceptives, that is something to discuss at the point of clinical assessment. For broader context on how semaglutide and weight management treatment interact with other medicines, our FAQs page covers common questions our prescribers field regularly.

The tablet is not available on the NHS at present, there is no NICE appraisal in place yet, so it is a private prescription for now. For anyone thinking about the cost side of that, what Wegovy tablets typically cost in the UK is covered separately. As with all the weight-loss medicines we offer, the single price at nume includes clinical assessment, the prescription, and tracked next-working-day delivery, there are no add-on fees.

What happens if you are already on the injection

People currently established on the 2.4 mg weekly injection can, subject to clinical assessment, move directly to the 25 mg tablet rather than restarting the titration from scratch. This is not automatic (a prescriber needs to review whether the switch is appropriate for you and confirm it at that point) but it does mean the transition is not necessarily a long process for those already at maintenance dose.

If you are considering a switch, or are new to semaglutide entirely and wondering which form to start with, the question of whether the pill form of Wegovy is accessible to you comes down to clinical suitability rather than availability. The MHRA has authorised the tablet; it is a matter of whether it is the right fit for your circumstances. Our prescribers (you can read about our clinical team on the clinical team page) review each consultation the same day it is submitted. If you are ready to find out whether oral semaglutide is an option for you, checking your eligibility starts with a free consultation.